org/ morph eus). HLA class I expression was assessed for HLA-A, -B, and -C, and HLA-DP , -DQ, and -DR for class II, as pre - viously described [39]. Differentially expressed genes post-treatment compared to baseline were assessed using the NOISeq tool [40] and were calculated for each patient with available biopsies (N01, N02, N03, and N07). Gene set enrichment analysis of the differen - tially expressed genes was performed using WebGestalt [41] and Gene Ontology mapping to the Biological Pro - cesses functional database. The artificial intelligence (AI) prediction platform used for immunogenic neoantigen prediction was the NEC Immune Profiler (NIP) [42]. The NIP software predicted each of the key determinants of antigen pres - entation (AP) for each somatic mutation, by predicting the potential of all tumor-specific mutated peptides to be efficiently presented by each of the patients Class I HLA-A and -B alleles. Statistics The sample size (n) represents the number of patients or samples analyzed.